NASHUA, New Hampshire - Conformal Medical, Inc., a leading medical device company specializing in the development of devices aimed at preventing stroke in patients with non-valvular atrial fibrillation, is pleased to announce the successful completion of its Series D funding round, raising an impressive $35 million. The funding round was led by SPRIG Equity, a prominent venture capital firm focused on healthcare investments.

Conformal Medical's innovative technology is designed to revolutionize left atrial appendage closure, enabling it to reach its full potential as a means of stroke prevention in patients with non-valvular atrial fibrillation. By addressing the critical need for advanced medical equipment in this field, Conformal Medical is poised to make a significant impact on patient outcomes and quality of life.

The $35 million raised in this funding round will be utilized to further accelerate the development and commercialization of Conformal Medical's groundbreaking devices. The company's mission is to provide healthcare professionals with effective tools to minimize the risk of stroke in patients with non-valvular atrial fibrillation, thus improving their overall well-being and reducing the burden on the healthcare system.

"We are thrilled to have successfully raised $35 million in our Series D funding round," said James Reinstein, Founder of Conformal Medical, Inc. "This investment will enable us to advance our innovative technology and bring it closer to the market. We are grateful to SPRIG Equity for their confidence in our vision and for their support in driving our mission forward."